{"id":"decitabine-combined-with-haag-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Tumor lysis syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decitabine is a hypomethylating agent that removes aberrant DNA methylation marks on tumor suppressor genes, restoring their expression and inducing differentiation and apoptosis in leukemic cells. The HAAG regimen provides intensive chemotherapy with multiple mechanisms of action. Together, this combination targets both epigenetic dysregulation and provides direct cytotoxic activity against leukemic blasts.","oneSentence":"Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, combined with HAAG chemotherapy (cytarabine, aclarubicin, amsacrine, granulocyte colony-stimulating factor) to enhance cytotoxic effects in hematologic malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:55.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), particularly in elderly or relapsed/refractory patients"},{"name":"Myelodysplastic syndrome (MDS)"}]},"trialDetails":[{"nctId":"NCT04446130","phase":"PHASE3","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":"Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia","enrollment":100},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Decitabine combined with HAAG Regimen","genericName":"Decitabine combined with HAAG Regimen","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, combined with HAAG chemotherapy (cytarabine, aclarubicin, amsacrine, granulocyte colony-stimulating factor) to enhance cytotoxic effects in hematologic malignancies. Used for Acute myeloid leukemia (AML), particularly in elderly or relapsed/refractory patients, Myelodysplastic syndrome (MDS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}